Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy

2 Aug 2016

Abstract excerpt

Triple negative breast cancer (TNBC) is a heterogeneous disease associated with poor clinical outcome and lack of targeted therapy. Here we show that prolactin (PRL) and its signaling pathway serve as a sub-classifier and predictor of pro-differentiation therapy in TNBC. Using immunohistochemistry and various gene expression in silica analyses we observed that prolactin receptor (PRLR) protein and mRNA levels are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Estrogen and related hormone effects
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27480353
DOI: 10.1038/srep30934

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential TherapyPMID 27480353Read ↗

A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.Semantic proximity Read ↗

Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment.Semantic proximity Read ↗

The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.Semantic proximity Read ↗

Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies.Semantic proximity Read ↗

Breast Cancer and Prolactin – New Mechanisms and ModelsSemantic proximity Read ↗

Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasivenessSemantic proximity Read ↗

Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative Breast CancerSemantic proximity Read ↗

Triple Negative Breast Cancer: A Multi-Omics Network Discovery Strategy for Candidate Targets and Driving PathwaysSemantic proximity Read ↗

Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.Semantic proximity Read ↗

Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analysesSemantic proximity Read ↗

Transforming growth factor-β signaling in tumor initiation, progression and therapy in breast cancer: an updateSemantic proximity Read ↗

Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.